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Abstract 16 
Measurement of serum galactomannan (GM), a polysaccharide fungal cell-wall 17 
component, is a non-invasive test for early diagnosis of invasive aspergillosis in 18 
humans. Feline upper respiratory tract (URT) aspergillosis is an emerging infectious 19 
disease in cats. Diagnosis requires biopsy for procurement of tissue specimens for 20 
cytological or histological detection of fungal hyphae and for fungal culture. The aim 21 
of this study was to evaluate serum GM measurement as a non-invasive diagnostic 22 
test for URT aspergillosis in cats. A one-stage, immunoenzymatic sandwich ELISA 23 
was used to detect serum GM in 4 groups of cats; Group 1 (URT aspergillosis) – 24 
confirmed URT aspergillosis (n=13, sinonasal aspergillosis (SNA) n=6, sino-orbital 25 
aspergillosis (SOA) n=7), Group 2 (URT other) – other URT diseases (n=15), Group 26 
3 (β-lactam) – cats treated with β-lactam antibiotics for non-respiratory tract disease 27 
(n=14), Group 4a – healthy young cats (≤ 1y of age, n=28), Group 4b – healthy adult 28 
cats (>1 y of age, n=16). One cat with SNA and two cats with SOA caused by an 29 
Aspergillus fumigatus-mimetic species, tested positive for serum GM. For a cut-off 30 
optical density index of 1.5, the overall sensitivity and specificity of the assay was 31 
23% and 78% respectively. False positive results occurred in 29 % of cats in Group 3 32 
and 32% of cats in Group 4a. Specificity increased to 90% when Groups 3 and 4a 33 
were excluded from the analysis.  Overall, serum GM measurement has a poor 34 
sensitivity but is a moderately specific, non-invasive screening test to rule out 35 
infection in patients with suspected feline upper respiratory tract aspergillosis. 36 
37 
3 
Introduction 38 
Feline upper respiratory tract (URT) aspergillosis has been increasingly recognised 39 
since it was first described by Wilkinson et al., in 1982, with over 50 cases reported 40 
across three continents. (Barachetti et al., 2009, Barrs et al., 2012a, Furrow & Groman 41 
2009, Giordano et al., 2010, Goodall et al., 1984, Hamilton et al., 2000, Kano et al., 42 
2008, Karnik et al., 2009, McLellan et al., 2006, Smith & Hoffman 2010, Tomsa et 43 
al., 2003,  Whitney et al., 2005, Wilkinson et al., 1982). Similar to canine sinonasal 44 
aspergillosis (SNA), infections caused by A. fumigatus are confined to the sinonasal 45 
cavity. However other Aspergillus fumigatus complex members cause more invasive 46 
disease that extends into the orbit and adjacent tissues in two-thirds of feline cases 47 
(Barrs et al., 2012a). Treatment of sino-orbital aspergillosis (SOA) is rarely successful 48 
and early initiation of therapy is precluded by failure to make a diagnosis until 49 
advanced-stage disease. 50 
51 
Galactomannan (GM), a water-soluble, heat-stable polysaccharide cell wall 52 
component of Aspergillus species is released into the circulation during hyphal 53 
invasion into tissue (Hope et al., 2005). Serum GM measurement is the most 54 
frequently used test for early diagnosis of invasive aspergillosis (IA) in at-risk human 55 
populations, although false positive results have been identified in young patients and 56 
those being treated with β-lactam antibiotics (Siemann et al., 1998, Zandijk et al., 57 
2008).  Serum GM detection is highly sensitive for diagnosis of systemic aspergillosis 58 
in dogs but has poor sensitivity and specificity for diagnosis of SNA in dogs (Billen et 59 
al., 2009, Garcia et al., 2012). In canine SNA fungal hyphae colonise sinonasal 60 
surface epithelium but do not penetrate the respiratory mucosa (Peeters et al., 2005). 61 
We hypothesised that in feline URT aspergillosis, given its more invasive nature, 62 
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infection would be accompanied by release of GM into the circulation. The aim of this 63 
study was to evaluate serum GM detection for the diagnosis of feline URT 64 
aspergillosis. 65 
66 
Materials and Methods 67 
Clinical data and serum were collected prospectively from cats with diagnosed URT 68 
aspergillosis (Group 1 – URT Aspergillosis), cats with URT signs not attributable to 69 
aspergillosis (Group 2 - URT Other), cats treated with β-lactam antibiotics (Group 3 - 70 
β-lactam) and healthy cats (Group 4a- Young Healthy and Group 4b - Adult Healthy 71 
group). Samples were collected with informed owner consent, according to the 72 
guidelines of the Animal Ethics Committee of the University of Sydney (AEC Ref 73 
No. N00/3-2009/2/4961).  Briefly, whole blood (1-2mL) was collected by jugular 74 
venipuncture into a plain tube, allowed to clot at room temperature, centrifuged and 75 
the serum decanted into a sterile microcentrifuge tube. Samples were stored at -80⁰C 76 
until analysis. Quantification of serum GM in all samples was performed by one of 77 
the authors (JW), who was blinded to the identity of the samples.  The assay was 78 
performed according to the manufacturer’s instructions using a one-stage, 79 
immunoenzymatic sandwich ELISA ( Platelia™ Aspergillus EIA, Bio-Rad, Marnes-80 
la-Coquette, France) including pre-treatment EDTA-heat extraction to dissociate 81 
immune complexes. The assay utilizes a rat monoclonal antibody, EB-A2, which 82 
binds to the galactofuran epitope of the GM antigen, specifically to the (1→5)-β-D-83 
galactofuranosyl (galf) side chains (Swanink et al., 1997).  84 
85 
Samples were run in duplicate in batches including a positive control, negative 86 
control, cut-off samples and a blank well.  The two most common cut-off indices 87 
5 
reported in the human literature, optical density index (ODI) 0.5 and 1.5, were used to 88 
determine positive results (Maertens et al., 2006). The mean reported intra-assay and 89 
inter-assay coefficients of variation (CV) of the Platelia™ Aspergillus EIA are 6.6%  90 
and 17.7%  respectively for low positive samples (ODI < 0.8) and 4.9% and 17.7% 91 
respectively for high positive samples (ODI > 2) (manufacturer’s information). 92 
93 
Cats 94 
Group 1 – URT Aspergillosis 95 
Inclusion criteria for cats with URT aspergillosis were the identification of fungal 96 
hyphae on cytology or histology of tissue from the sinonasal cavity or orbit, a positive 97 
fungal culture and molecular identification on the basis of PCR and sequencing of the 98 
ITS, β-tubulin and calmodulin gene regions (Barrs et al., 2012b).  Samples were 99 
collected before antifungal therapy and in a subset of cats serial samples were also 100 
collected after diagnosis during antifungal therapy. Where more than 1 sample was 101 
collected, only 1 sample from each cat collected at diagnosis was included in the 102 
evaluation of the ELISA. Cats were classified as having SNA or SOA based on the 103 
presence (SOA) or absence (SNA) of a retrobulbar mass on computed tomography or 104 
magnetic resonance imaging at diagnosis.  Signalment, history, physical examination 105 
findings, intercurrent disease and results of culture and molecular identification results 106 
were recorded.  107 
108 
Group 2 – URT Other  109 
Inclusion criteria for cats with URT disease not attributable to aspergillosis were (i) 110 
consistent clinical signs e.g. sneezing, nasal discharge (ii) absence of fungal hyphae 111 
on cytology or histology of tissue collected from the sinonasal cavity, and/or (iii) 112 
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serological, histopathological or endoscopic diagnosis of another URT disease. 113 
Standard diagnostic investigations included latex antigen cryptococcal serology 114 
(CALAS® Meridian Biosciences), upper airway endoscopy, advanced imaging 115 
(CT/MRI) and biopsy.  Only cats with a definitive diagnosis were included in this 116 
group.   Samples were collected prior to the initiation of therapy. 117 
118 
Group 3 – β-lactam 119 
Inclusion criteria were (i) the absence of respiratory tract signs and (ii) ongoing 120 
treatment with amoxicillin-clavulanate or ticarcillin-clavulanate which had been 121 
initiated at least 24 hours earlier.   122 
123 
Group 4 – Healthy Cats 124 
Healthy cats presented to the Valentine Charlton Cat Centre for routine desexing, 125 
vaccination or annual health check were included if there was no evidence of recent or 126 
current clinical disease or medication based on history and physical examination.  127 
This group was further stratified according to age, as follows; Group 4a, 1 year of age 128 
and under, and Group 4b, older than 1 year.  129 
130 
Statistical Analyses 131 
Statistical analyses were performed using GraphPad Prism® versions 5.04 (GraphPad 132 
Software, Inc. 2010).  Age and GM ODI were compared between groups 1 to 4 using 133 
Kruskal-Wallis and Dunn’s Multiple Comparison Tests.  Mann-Whitney tests were 134 
used to compare the median ODIs of Group 1 with different forms of disease and 135 
different causative agents.  136 
137 
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Three different negative control groups were used when evaluating the specificity of 138 
the ELISA for the diagnosis of feline URT aspergillosis.  The first control group 139 
comprised all the aspergillosis-negative cats (Groups 2, 3, 4a and 4b).  A second 140 
evaluation of specificity was performed omitting groups 3 and 4a, which were 141 
predicted to have frequent false positive results.  The third control group 142 
compromised only Group 2, the cases most likely to be tested in a clinical situation. 143 
For each cut-off ODI and control group, the sensitivity and specificity were calculated 144 
with 95% exact confidence intervals using a contingency table.     145 
146 
Results 147 
Cats 148 
There were 13 cats in Group 1, 15 in Group 2, 14 in Group 3 and 44 in Group 4 149 
including 28 in Group 4a and 16 in Group 4b.  Serum samples were collected from 150 
Group 1 cats before treatment, including 6 neutered males and 7 neutered females 151 
ranging in age from 2 to 14 years (mean 7y, median 5y) (Table 1).   Two to three 152 
serial serum samples were collected from 3 Group 1 cats (Table 2). All 15 Group 2 153 
cats were neutered (8 females, 7 males) and ranged in age from 2 to 20 years (mean 154 
9.7y, median 10y).   URT diseases in Group 2 cats included neoplasia (6), 155 
lymphoplasmacytic rhinitis (4), cryptococcosis (2), laryngeal paralysis (2) and 156 
nasopharyngeal stenosis (1).  All 14 cats in Group 3 were neutered (7 females, 7 157 
males) and ranged in age from 1 to 16 years (mean 10.7y, median 12 y).  Diagnoses in 158 
Group 3 cats included enteropathies (3), urinary tract infection (3), pancreatitis (2), 159 
neoplasia (2), hepatic lipidosis (1), tooth root abscess (1), pemphigus foliaceous (1) 160 
and cat bite abscess (1). All 28 cats in Group 4a were entire (17 females, 11 males) 161 
and 1 year of age or less (mean 0.5y, median 0.4y).  The 16 cats in Group 4b included 162 
8 
12 females (2 entire, 10 neutered) and 4 neutered males ranging in age from 1.3 to 10 163 
year (mean 4.8y, median 4y). There was no significant difference in age between 164 
Groups 1, 2, 3 and 4b.  The median age of Group 4a was significantly different to all 165 
other groups (P<0.05). 166 
167 
Galactomannan Quantification 168 
There was no significant difference between groups regarding the GM ODI (P=0.31) 169 
(Figure 1).  The median GM ODI was 0.32 (range 0.14-5.34) in Group 1, 0.38 (0.15-170 
6.13) in Group 2, 0.44 (0.17-6.10) in Group 3, 0.48 (range 0.15-6.66) in Group 4a and 171 
0.52 (range 0.16-5.36) in Group 4b. Thirty-five cats had a GM ODI greater than 0.5 172 
and 19 cats had an ODI greater than 1.5. 173 
174 
A serum GM ODI of greater than 0.5 was detected in 3 (23%) Group 1 cats, 4 (27%) 175 
Group 2 cats, 7 (50%) cats Group 3 cats, 13 (46%) Group 4a cats and 8 (50%) Group 176 
4b cats. A serum GM ODI of greater than 1.5 was detected in 3 (23%) Group 1 cats, 1 177 
(7%) Group 2 cat, 4 (29%) Group 3 cats, 9 (32%) Group 4 a cats and 2 (13%) Group 178 
4b cats.  The sensitivity and specificity of serum GM measurement in the diagnosis of 179 
feline URT aspergillosis using different negative control groups is described in Table 180 
3. 181 
182 
Of the 13 cats with URT aspergillosis, 6 (46%) had SNA (median ODI = 0.34) and 7 183 
(53.8%) had SOA (median ODI = 0.27) (Table 1).  There was no significant 184 
difference in the median serum GM ODI between these groups (P=0.95).  Three URT 185 
aspergillosis cats were infected with Aspergillus fumigatus, one with Aspergillus 186 
lentulus, one with Aspergillus thermomutatus/Neosartorya pseudofischeri and 8 cats 187 
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with a novel Aspergillus species (Barrs et al., 2012b).  The only cats with GM ODI 188 
greater than twice the cut-off level were infected with the novel Aspergillus spp. 189 
(Table 1)  although there was no statistically significant difference between the 190 
median ODI of all cats infected with the novel Aspergillus spp. (median ODI=0.29) 191 
and the other Group 1 cats (median ODI = 0.34, P=0.52). All cats tested for feline 192 
immunodeficiency virus and feline leukaemia virus (n=8) were seronegative. 193 
194 
Three cats (A, B and C) from Group 1 had serum samples available at diagnosis and 195 
after the initiation of treatment (Table 2).  All 3 had SOA caused by a novel 196 
Aspergillus species. In Case A GM was negative both at diagnosis and during 197 
treatment.   Case B had progression of clinical signs and extension into the CNS 198 
despite aggressive antifungal therapy. The second serum sample was collected shortly 199 
before euthanasia.  Case C had a high GM ODI at presentation that decreased slightly 200 
after commencing antifungal therapy but increased again shortly before the cat was 201 
euthanased due to disease progression. 202 
203 
Discussion 204 
The diagnostic sensitivity and specificity of a laboratory test describes its ability to 205 
identify affected and non-affected subjects respectively. In practice, discrimination by 206 
a single test is rarely absolute and a cut-off value is selected for a continuous variable, 207 
such as ODI, to maximise performance. Receiver operating characteristics (ROC) 208 
analysis can be used to evaluate diagnostic performance and this is the preferred 209 
method to determine the optimum cut-off value (Kaufmann et al., 2005).  In this 210 
study, the median ODI for the URT aspergillosis group was not significantly different 211 
to the control groups, meaning that ROC analysis would not be meaningful.  For this 212 
10 
reason, contingency analysis was used for evaluation of serum GM for the diagnosis 213 
of feline URT aspergillosis, using published ODI cut-off values to determine 214 
sensitivity and specificity (Maertens et al., 2006). 215 
216 
Specificity of the assay in this study was highest at an ODI of 1.5. The high frequency 217 
of false positive results in certain groups impacted the calculation of specificity. When 218 
all unaffected cases (Groups 2, 3 and 4) were considered together, the specificity 219 
using a cut-off ODI of 1.5 was 78% (Table 3).  However, by removing Group 3 and 220 
4a cats from the analysis, the specificity of the ELISA was markedly improved to 221 
90% (cut-off index 1.5).  Among the 15 Group 2 cats, the most clinically relevant 222 
control group, a single false positive result was returned from a cat with nasal 223 
cryptococcosis.  Cryptococcosis is associated with high false positive GM results in 224 
human and canine patients (Xavier et al., 2009, Garcia et al., 2012). It is thought that 225 
C. neoformans galactoxylomannan contains cross-reactive epitopes that mimic 226 
Aspergillus GM (Dalle et al., 2005).  Clinically, the exclusion of cats with a positive 227 
galactomannan titre that are infected with C. neoformans can be identified using the 228 
commercially available non-invasive latex cryptococcal antigen test. 229 
230 
The high frequency of false positive result among Group 3 and 4a cats in this study 231 
parallels findings in human studies. False-positives were recorded in 44% of 232 
paediatric patients, 83% of premature neonates and in 47% of human patients on 233 
amoxicillin-clavulanate therapy (Herbrecht et al., 2002, Siemann et al., 1998, Zandijk 234 
et al., 2008).  It has been proposed that since the Penicillium spp., from which β-235 
lactam antibiotics are manufactured produce GM, its introduction into the antibiotic 236 
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during preparation is the likely cause of this erroneous result (Hope et al., 2005).  237 
These results differ from those seen in dogs in which 3/18 dogs treated with 238 
penicillins but without aspergillosis had positive galactomannan (Garcia et al., 2012).   239 
The sensitivity of the Platelia™ Aspergillus EIA for diagnosis of feline aspergillosis 240 
was poor at 23%. Reducing the ODI cut-off from 1.5 to 0.5, which would favour 241 
increased sensitivity over specificity, and which may have been acceptable for clinical 242 
application as a screening test to identify cases appropriate for further diagnostics, had 243 
no effect on the sensitivity.  Several factors may have contributed to the failure to 244 
identify all Group 1 cats. In humans, the sensitivity of GM ELISA is typically greater 245 
than 90% in neutropenic patients (Hachem et al., 2009,) while in patients with solid-246 
organ transplants or underlying pulmonary diseases, who are generally not 247 
neutropenic, the sensitivity is less than 30%  using an ODI cut-off of 0.5 (Kitasato et 248 
al., 2009, Pfeiffer et al., 2006).  The inability to detect circulating GM in 249 
immunocompetent patients is, in part due to antigen clearance or complexing by 250 
circulating anti-Aspergillus antibodies (Herbrecht et al., 2002).  The sensitivity of GM 251 
detection is lower in patients with circulating antibodies at the onset of Aspergillus252 
infection compared with seronegative patients (Herbrecht et al., 2002). Similar to the 253 
majority of reports of feline URT aspergillosis, none of the Group 1 cats in this study 254 
was known to have immunosuppressive disease (Barrs et al., 2012a). Sample EDTA-255 
heat extraction pre-treatment to dissociate immune complexes could cause 256 
degradation of antigen which would reduce sensitivity (Menninck-Kersten et al., 257 
2004). Alternative methods of complex dissociation such as addition of dithiothreitol 258 
or a protease (pronase) (Stockman & Roberts 1983) were not investigated. 259 
260 
12 
While we hypothesised that the invasive nature of SOA would result in GM release 261 
into the circulation, the degree of angioinvasion in these immunocompetent cats may 262 
be less than that in neutropenic humans with invasive aspergillosis. Further the 263 
granulomatous inflammatory response that occurs in SOA (Barachetti et al., 2009, 264 
Barrs et al., 2012a, Giordano et al., 2010, Smith & Hoffmann 2010) could prevent 265 
GM release. Finally, a local environment deficient in oxygen and glucose can restrict 266 
fungal growth and GM release (Mennink-Kersten et al., 2004). This mechanism could 267 
be operating in areas of infarction and necrosis seen in the orbital and paranasal 268 
granulomas from cats with SOA (Barrs et al., 2012a) and may contribute to reduced 269 
circulating GM in the later stages of SOA. 270 
271 
In vitro studies have shown that the amount of GM released by Aspergillus species is 272 
species-dependent (Swanink et al., 1997). All of the Group 1 cats that were positive 273 
on the serum GM ELISA were infected with the same novel Aspergillus fumigatus-274 
mimetic species which is closely related to Aspergillus viridinutans (Barrs et al, 275 
2012b).  One of these cats had SNA at diagnosis. Invasive sinonasal mucosal infection 276 
could account for the positive GM result in this case. In one study the sensitivity of 277 
the GM assay was significantly higher for IA due to non-fumigatus Aspergillus 278 
species than for patients with IA due to A. fumigatus infection (Hachem et al., 2009).   279 
Pretreatment concentration of serum GM based on retention above a 50-kDa cut-off 280 
filter has been found to markedly increase the sensitivity of the Platelia™ Aspergillus281 
EIA in human sera (Mennink-Kersten et al.,. 2008). This modification is worthy of 282 
further investigation for feline samples.  283 
284 
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Limited samples were available for longitudinal study of serum GM in individual 285 
patients. In case A, serum GM values were consistently negative on ELISA, even 286 
when the cat came out of remission. It should be noted that this cat had the best 287 
response of any of the SOA cases treated and is in remission at the time of writing, 5 288 
years from first diagnosis. It may be that the negative serum GM in case A is a 289 
reflection of a superior immune response compared with other cases.  GM levels in 290 
case B decreased dramatically during aggressive antifungal therapy. Concurrent 291 
antifungal treatment is a recognised cause of false-negative results in humans with 292 
invasive aspergillosis (Hope et al., 2005). Unfortunately, the decrease in GM did not 293 
correlate with clinical improvement and case B was euthanased because of 294 
progressive disease with central nervous system involvement. Case C had a 295 
persistently high GM and was euthanased due to disease progression despite 296 
aggressive treatment.  This result may reflect an inadequate immune response in this 297 
patient.   298 
299 
The study of naturally acquired disease in a clinical setting is arguably the most 300 
relevant source of data where the goal is to diagnose and treat field cases. The 301 
stringent criteria used to define the affected population here provide a robust gold 302 
standard for diagnostic evaluation of the assay. Although samples numbers were 303 
limited, the group of affected cats studied represents 28% of the total reported cases of 304 
feline URT aspergillosis.  The reported intra-assay CV for the Platelia™ Aspergillus305 
EIA is relatively low indicating that this is unlikely to be a significant limitation of the 306 
assay.  The inter-assay CV is slightly above the recognised acceptable limit for a 307 
biological assay (10-15%).  However, despite this the assay is used extensively in 308 
14 
human medicine and has been recently shown to be of diagnostic benefit in the dogs 309 
with systemic aspergillosis (Garcia et al., 2012).   310 
311 
In conclusion, GM quantification by ELISA is not a reliable test for the early, non-312 
invasive diagnosis of feline URT aspergillosis.  However, in cats with upper 313 
respiratory signs it has good specificity.  Investigation of serological detection of anti-314 
Aspergillus antibodies for early non-invasive diagnosis of feline URTA is warranted.   315 
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Table 1  
Fungal species and ODI for URT Aspergillosis cats. 
Case Age Sex Breed Form FIV/FeLV 
Serology 
Fungal Species ODI 
1 11 FN Persian SNA Not tested A. fumigatus 0.426
2 12 MN DLH SNA Negative A. fumigatus 0.337 
3 14 FN Persian  
cross 
SNA Not tested A. lentulus 0.335
4 7 MN Persian SNA Negative A. fumigatus 0.141
5 2 MN Rag Doll SNA Not tested A. thermomutatus/ 
Neosartorya pseudofischeri 
0.140 
6 13 MN DSH SNA Negative Aspergillus spp. nov. 5.339 
7 2 MN Himalayan SOA Negative Aspergillus spp. nov. 4.961
8 2 FN DSH SOA Negative Aspergillus spp. nov. 0.318 
9 2 FN DSH SOA Negative Aspergillus spp. nov. 0.248
10 3 MN DSH SOA Negative Aspergillus spp. nov. 5.318 
11 8 FN Persian SOA Not tested Aspergillus spp. nov. 0.265
12 5 FN DSH SOA Not tested Aspergillus spp. nov. 0.206 
13 5 FN Cornish 
Rex 
SOA Negative Aspergillus spp. nov. 0.155
DSH, Domestic shorthair; DLH, Domestic longhair; SNA, sino-orbital aspergillosis; SNA, sino-nasal 457 
aspergillosis; ODI, optical density index 458 
459 
460 
461 
462 
463 
464 
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Table 2  
Galactomannan ODI for URT Aspergillosis cats with multiple samples. 
Signalment Collection Date Clinical Data ODI 
Case A 
2y FN Cornish Rex 
12.4.2007 No clinical signs, off treatment 0.306 
1.12.2007 No clinical signs, off treatment 0.386
14.10.2009 Clinical Signs (relapse), no 
treatment 
0.155* 
23.2.2010 No clinical signs, on treatment 0.281 
Case B 
3y MN DSH 
7.3.2008 Clinical Signs, no treatment 5.318* 
28.4.2008 On treatment, clinical signs 0.367
Case C 
2y MN Himalayan 
26.2.2007 Clinical Signs, no treatment 4.08* 
2.3.2007 Clinical Signs, on treatment 3.728
10.4.2007 Clinical Signs, on treatment 4.961 
FN, female neutered; MN, male neutered; DSH, domestic shorthair; ODI, optical density index;  465 
* ODI used in statistical calculations 466 
467 
468 
469 
470 
471 
472 
473 
474 
475 
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Table 3 
Sensitivity and specificity of serum galactomannan measurement for diagnosing URT 
aspergillosis in cats evaluated by comparing confirmed URT aspergillosis cats (Group 
1; n = 26) with different negative control groups*. 
Negative Control 
Groups 
0.5 ODI cut-off 1.5 ODI cut-off 
Sensitivity
(95% CI) 
Specificity
(95% CI) 
Sensitivity
(95% CI) 
Specificity
(95% CI) 
2, 3 & 4 23.08% 
(5.04-53.81) 
56.16% 
(44.05-67.76) 
23.08% 
(5.04-53.81) 
78.08% 
(66.86-86.92) 
2 & 4b 23.08% 
(5.04-53.81) 
61.29% 
(42.19-78.15) 
23.08% 
(5.04-53.81) 
90.32% 
(74.25-97.96) 
2 23.08%
(5.04-53.81) 
73.33%
(44.90-92.21) 
23.08%
(5.04-53.81) 
93.33%
(68.05-99.83) 
CI, confidence interval; ODI, optical density index 476 
*Group 2 (URT other) – other URT diseases (n=15); Group 3 (β-lactam) – cats treated with β-lactam 477 
antibiotics for non-respiratory tract disease (n=14); Group 4a – healthy young cats (≤ 1y of age, n=28); 478 
Group 4b – healthy adult cats (>1 y of age, n=16).479 
480 
481 
482 
483 
484 
485 
486 
487 
488 
489 
490 
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